Date:November_	_26 <sup>th</sup> , 2022
Your Name:	Jingya Zhao
Manuscript Title:	Real-world Experience of Arbidol for Omicron variant of SARS-CoV-2
Manuscript numbe	r (if known): JTD-22-980

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)
		none (add rows as needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	Shanghai Key Laboratory	Diagnosis and Treatment of Respiratory Infectious
	manuscript (e.g., funding,	of Emergency Prevention	Disease (20dz2261100)
	provision of study materials,	Cultivation Project of	20dz2210500
	medical writing, article	Shanghai Major Infectious	
	processing charges, etc.)	Disease Research Base	
	No time limit for this item.	Shanghai Municipal Key	shslczdzk02202
		Clinical Specialty	
		Shanghai Top-Priority	2017ZZ02014
		Clinical Key Disciplines	
		Construction Project	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
2	in item #1 above).	Nana	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	

6	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement:

Date:November_27 <sup>th</sup> , 2022 <sub>.</sub>		
Your Name: Yong Li_		
Manuscript Title:Real-	world Experience of Arbidol for Omicron variant of SARS-CoV-2	
Manuscript number (if known	): JTD-22-980	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Shanghai Key Laboratory of Emergency Prevention Cultivation Project of Shanghai Major Infectious Disease Research Base Shanghai Municipal Key Clinical Specialty Shanghai Top-Priority Clinical Key Disciplines Construction Project	Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100)  20dz2210500  shslczdzk02202  2017ZZ02014
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	30 months
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement:

ate:November_27 <sup>th</sup> , 2022			
Your Name:	Rong Chen		
Manuscript Title:	Real-world Experience of Arbidol for Omicron variant of SARS-CoV-2		
Manuscript numbe	r (if known): JTD-22-980		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	Shanghai Key Laboratory	Diagnosis and Treatment of Respiratory Infectious
	manuscript (e.g., funding,	of Emergency Prevention	Disease (20dz2261100)
	provision of study materials,	Cultivation Project of	20dz2210500
	medical writing, article	Shanghai Major Infectious	
	processing charges, etc.)	Disease Research Base	
	No time limit for this item.	Shanghai Municipal Key	shslczdzk02202
		Clinical Specialty	
		Shanghai Top-Priority	2017ZZ02014
		Clinical Key Disciplines	
		Construction Project	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
2	in item #1 above).	Name	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	

6	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement:

Pate:November_27 <sup>th</sup> , 2022			
Your Name:	Yanping Xu		
Manuscript Title:	Real-world Experience of Arbidol for Omicron variant of SARS-CoV-2		
Manuscript numbe	r (if known): JTD-22-980		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Shanghai Key Laboratory of Emergency Prevention Cultivation Project of Shanghai Major Infectious Disease Research Base Shanghai Municipal Key Clinical Specialty Shanghai Top-Priority Clinical Key Disciplines Construction Project	Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100)  20dz2210500  shslczdzk02202  2017ZZ02014
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement:

Date:November_	ate:November_27 <sup>th</sup> , 2022			
Your Name:	Qingyuan Yang			
Manuscript Title:	Real-world Experience of Arbidol for Omicron variant of SARS-CoV-2			
Manuscript number	(if known): JTD-22-980			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Shanghai Key Laboratory of Emergency Prevention Cultivation Project of Shanghai Major Infectious Disease Research Base Shanghai Municipal Key Clinical Specialty Shanghai Top-Priority Clinical Key Disciplines Construction Project	Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100)  20dz2210500  shslczdzk02202  2017ZZ02014
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	30 months
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement:

Date:November_	ate:November_27 <sup>th</sup> , 2022			
Your Name:	Haiqing Zhang			
Manuscript Title:	Real-world Experience of Arbidol for Omicron variant of SARS-CoV-2			
Manuscript number	· (if known): JTD-22-980			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Shanghai Key Laboratory of Emergency Prevention Cultivation Project of Shanghai Major Infectious Disease Research Base Shanghai Municipal Key Clinical Specialty Shanghai Top-Priority Clinical Key Disciplines Construction Project	Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100)  20dz2210500  shslczdzk02202  2017ZZ02014
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement:

Date:November_	_26 <sup>tn</sup> , 2022		
Your Name:	Zhengxin Yin _		
Manuscript Title:	Real-world	xperience of Arbidol for Omicron variant of SARS-CoV-2	
Manuscript numbe	r (if known):	JTD-22-980	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Shanghai Key Laboratory of Emergency Prevention Cultivation Project of Shanghai Major Infectious Disease Research Base Shanghai Municipal Key Clinical Specialty Shanghai Top-Priority Clinical Key Disciplines Construction Project	Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100)  20dz2210500  shslczdzk02202  2017ZZ02014
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement:

Date:November_28 <sup>th</sup>	, 2022	
Your Name: We	iting Gu	
Manuscript Title:	Real-world Experience of Arbidol for Omicron variant of SARS-CoV-2	
Manuscript number (if	known): JTD-22-980	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Shanghai Key Laboratory of Emergency Prevention Cultivation Project of Shanghai Major Infectious Disease Research Base Shanghai Municipal Key Clinical Specialty Shanghai Top-Priority Clinical Key Disciplines Construction Project	Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100)  20dz2210500  shslczdzk02202  2017ZZ02014
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement:

Date:November_26 <sup>th</sup> , 2022			
Your Name: J	insong Hu		
Manuscript Title:	Real-world Experience of Arbidol for Omicron variant of SARS-CoV-2		
Manuscript number	(if known): JTD-22-980		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Shanghai Key Laboratory of Emergency Prevention Cultivation Project of Shanghai Major Infectious Disease Research Base Shanghai Municipal Key Clinical Specialty Shanghai Top-Priority Clinical Key Disciplines Construction Project	Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100)  20dz2210500  shslczdzk02202  2017ZZ02014
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement:

Pate:November_26 <sup>th</sup> , 2022				
Your Name: Li Chen				
Manuscript Title: Rea	l-world Experience of Arbidol for Omicron variant of SARS-CoV-2			
Manuscript number (if know	n): JTD-22-980			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Shanghai Key Laboratory of Emergency Prevention Cultivation Project of Shanghai Major Infectious Disease Research Base Shanghai Municipal Key Clinical Specialty Shanghai Top-Priority Clinical Key Disciplines Construction Project	Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100)  20dz2210500  shslczdzk02202  2017ZZ02014
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement:

ate:November_28 <sup>th</sup> , 2022				
Your Name:]	Jian Li			
Manuscript Title:	Real-world	<b>Experience of Arbidol for</b>	Omicron variant of SARS-CoV-2	
Manuscript number	(if known):	JTD-22-980		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Shanghai Key Laboratory of Emergency Prevention Cultivation Project of Shanghai Major Infectious Disease Research Base Shanghai Municipal Key Clinical Specialty	Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100)  20dz2210500  shslczdzk02202
		Shanghai Top-Priority Clinical Key Disciplines Construction Project	2017ZZ02014
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement:

ate:November_27 <sup>th</sup> , 2022			
Your Name:	Guang Ning		
Manuscript Title:	Real-world Experience of Arbidol for Omicron variant of SARS-CoV-2		
Manuscript numbe	(if known): JTD-22-980		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Shanghai Key Laboratory of Emergency Prevention Cultivation Project of Shanghai Major Infectious Disease Research Base Shanghai Municipal Key Clinical Specialty Shanghai Top-Priority Clinical Key Disciplines Construction Project	Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100)  20dz2210500  shslczdzk02202  2017ZZ02014
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement:

Oate:November_27 <sup>tn</sup> , 2022				
our Name: Qijian Chen				
Manuscript Title:	Real-world Experience of Arbidol for Omicron variant of SARS-CoV-2			
Manuscript numbe	r (if known): JTD-22-980			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Shanghai Key Laboratory of Emergency Prevention Cultivation Project of Shanghai Major Infectious Disease Research Base Shanghai Municipal Key Clinical Specialty Shanghai Top-Priority Clinical Key Disciplines Construction Project	Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100)  20dz2210500  shslczdzk02202  2017ZZ02014
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	30 months
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement:

Date:November_27 <sup>th</sup> , 2022				
Your Name:	Min Zhou			
Manuscript Title:	Real-world Experience of Arbidol for Omicron variant of SARS-CoV-2			
Manuscript numbe	r (if known): JTD-22-980			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Shanghai Key Laboratory of Emergency Prevention Cultivation Project of Shanghai Major Infectious Disease Research Base Shanghai Municipal Key Clinical Specialty Shanghai Top-Priority Clinical Key Disciplines Construction Project	Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100)  20dz2210500  shslczdzk02202  2017ZZ02014
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement:

Date:November_27 <sup>tn</sup> , 2022				
our Name: Jieming Qu				
Manuscript Title:	Real-world Experience of Arbidol for Omicron variant of SARS-CoV-2			
Manuscript number (i	f known): JTD-22-980			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Shanghai Key Laboratory of Emergency Prevention Cultivation Project of Shanghai Major Infectious Disease Research Base Shanghai Municipal Key Clinical Specialty Shanghai Top-Priority Clinical Key Disciplines Construction Project	Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100)  20dz2210500  shslczdzk02202  2017ZZ02014
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Disease (20dz2261100), Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500), Shanghai Municipal Key Clinical Specialty (shslczdzk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014).

Please place an "X" next to the following statement to indicate your agreement: